drugset / Trial / NCT02606409
Dexmedetomidine Versus Propofol for Prolonged Sedation in Poly Traumatized Mechanically Ventilated Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
Dexmedetomidine, a central and peripheral α2-receptor agonist distinct from GABA receptor for benzodiazepines and propofol, has been approved by the US Food and Drug Administration only for use up to 24 h in mechanically ventilated patients. The investigators aim to compare dexmedetomidine with propofol for sedation \>24h in poly traumatized mechanically ventilated patients.
Timeline
- Start
- 2015-11
- Primary completion
- 2016-06
- Completion
- 2016-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dexmedetomidine | Other / unclassified | 0.2 ug/kg | Intravenous |
| Comparator | Dexmedetomidine | Other / unclassified | 0.7 ug/kg | Intravenous |
| Comparator | Dexmedetomidine | Other / unclassified | 7 ug/kg | Intravenous |
| Comparator | Propofol | Small molecule | 10 ug/kg | — |
| Comparator | Propofol | Small molecule | 70 ug/kg | — |
Indications
No indication recorded.